Critically, alectinib is effective for ALK+ NSCLC pts with a history of prior crizotinib treatment [8] and ceritinib has been shown to demonstrate high efficacy for pts with ALK+ NSCLC treated with or without prior therapy with crizotinib [9]. This evidence concerns the gene ALK and non-small cell lung carcinoma.